AI Article Synopsis
- The study examined the implementation of forced expiratory volume (FEV) telemonitoring for pediatric asthma during the COVID-19 pandemic, highlighting the perceptions of both patients and health care professionals (HCPs).
- Findings from surveys indicated a high acceptance of FEV home monitoring, with participants believing it improved asthma control and self-management, though concerns about device reliability and self-administered lung function tests were noted.
- Overall, while both patients and HCPs found value in the online monitoring, usage frequency varied significantly, suggesting that monitoring strategies should be personalized to meet individual patient goals.
Article Abstract
Background: The COVID-19 pandemic has boosted the use of forced expiratory volume in 1 second (FEV) telemonitoring in pediatric asthma, but a consensus on its most efficient and effective implementation is still lacking. To find answers, it is important to study how such an intervention is perceived, experienced, and used by both patients and health care professionals (HCPs).
Objective: The aim of this study was to provide perspectives on how FEV home monitoring should be used in pediatric asthma.
Methods: This is a qualitative, multicenter, prospective, observational study which included patients with asthma aged 6-16 and HCPs. Primary outcomes were results of 2 surveys that were sent to all participants at study start and after 3-4 months. Secondary outcomes consisted of FEV device usage during 4 months after receiving the FEV device.
Results: A total of 39 participants (26 patients and 13 HCPs) were included in this study. Survey response rates were 97% (38/39) at the start and 87% (34/39) at the end of the study. Both patients and HCPs were receptive toward online FEV home monitoring and found it contributive to asthma control, self-management, and disease perception. The main concerns were about reliability of the FEV device and validity of home-performed lung function maneuvers. FEV devices were used with a median frequency of 7.5 (IQR 3.3-25.5) during the 4-month study period.
Conclusions: Patients and HCPs are receptive toward online FEV home monitoring. Frequency of measurements varied largely among individuals, yet perceived benefits remained similar. This emphasizes that online FEV home monitoring strategies should be used as a means to reach individual goals, rather than being a goal on their own.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567151 | PMC |
| http://dx.doi.org/10.2196/29218 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.
Lancet Respir Med
December 2024
Population Policy and Practice Department, UCL Great Ormond Street Institute of Child Health, University College London, London, UK; Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK. Electronic address:
Article Synopsis
- Vanzacaftor-tezacaftor-deutivacaftor is a new CFTR modulator showing safety and effectiveness in phase 2 trials for adults with cystic fibrosis, leading to a study evaluating its use in children aged 6-11.
- This phase 3 trial, called RIDGELINE, involved participants from 33 clinical sites across eight countries, focusing on children with specific CFTR variants and stable health conditions.
- The study aimed to assess the drug's safety, tolerability, and efficacy over 24 weeks, with primary outcomes evaluated through various health metrics and participant feedback.
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.
Lancet Respir Med
December 2024
Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK. Electronic address:
Background: The goal of cystic fibrosis transmembrane conductance regulator (CFTR) modulators is to reach normal CFTR function in people with cystic fibrosis. Vanzacaftor-tezacaftor-deutivacaftor restored CFTR function in vitro and in phase 2 trials in participants aged 18 years and older resulting in improvements in CFTR function, as measured by sweat chloride concentrations and lung function as measured by spirometry. We aimed to evaluate the efficacy and safety of vanzacaftor-tezacaftor-deutivacaftor compared with standard of care elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older.
View Article and Find Full Text PDFAssociation of Forced Expiratory Volume in 0.5s With All-Cause Mortality Risk in Adults.
Arch Bronconeumol
December 2024
State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease & National Center for Respiratory Medicine & Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; Guangzhou National Laboratory, Guangzhou, China. Electronic address:
Introduction: Previous studies have proposed forced expiratory volume in 0.5s (FEV) to determine health outcomes in infants and young children, but few studies exist in adults. This study aims to investigate the associations between FEV and all-cause mortality in adults.
View Article and Find Full Text PDFSuccessful Therapy over 12 Months of People with Cystic Fibrosis with Rare Non-phe508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations with Elexacaftor/Tezacaftor/Ivacaftor (ETI).
Adv Respir Med
December 2024
Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm University, 89075 Ulm, Germany.
Elexacaftor/Tezacaftor/Ivacaftor (ETI) is a CFTR modulator therapy approved for people with cystic fibrosis (pwCF) who have at least one phe508del mutation. However, its approval in the European Union (EU) for pwCF with non-phe508del mutations is lacking, because data on treatment response in this subgroup are scarce. This retrospective observational study evaluated six pwCF (ages 6 to 66) with responsive CFTR mutations (M1101K, R347P, 2789+5G>A, G551D) undergoing off-label ETI therapy.
View Article and Find Full Text PDFA Wearable Device with Triboelectric Nanogenerator Sensing for Respiration and Spirometry Monitoring.
ACS Sens
December 2024
Department of Electrical and Computer Systems Engineering, Monash University, Wellington Rd, Clayton, VIC 3800, Australia.
Wearable devices have been developed for the continuous and long-term monitoring of respiration. Although current wearable devices are able to measure the respiration rate, extracting breathing volume has been challenging. In this paper, we propose a wearable respiration monitoring sensor based on triboelectric nanogenerator (TENG) technology.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!